BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO
BridgeBio Pharma sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
BridgeBio Pharma Annual SG&A Expenses (Millions of US $) |
2023 |
$151 |
2022 |
$143 |
2021 |
$192 |
2020 |
$146 |
2019 |
$94 |
2018 |
$44 |
2017 |
$13 |
BridgeBio Pharma Quarterly SG&A Expenses (Millions of US $) |
2024-09-30 |
$69 |
2024-06-30 |
$60 |
2024-03-31 |
$66 |
2023-12-31 |
$48 |
2023-09-30 |
$36 |
2023-06-30 |
$36 |
2023-03-31 |
$31 |
2022-12-31 |
$32 |
2022-09-30 |
$31 |
2022-06-30 |
$36 |
2022-03-31 |
$44 |
2021-12-31 |
$55 |
2021-09-30 |
$46 |
2021-06-30 |
$46 |
2021-03-31 |
$45 |
2020-12-31 |
$37 |
2020-09-30 |
$36 |
2020-06-30 |
$38 |
2020-03-31 |
$34 |
2019-12-31 |
$35 |
2019-09-30 |
$23 |
2019-06-30 |
$17 |
2019-03-31 |
$19 |
2018-12-31 |
|
2018-09-30 |
$10 |
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|